Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 11-19 , February 2003

Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review

  • C Nieder

      Affiliations

    • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, Munich, Germany
    • Corresponding Author InformationCorrespondence to: C. Nieder, Department of Radiation Oncology, Klinikum rechts der lsar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germay. Tel.: +49-4140-4501; Fax: +49-4140-4880
    • ,
  • T Licht

      Affiliations

    • Department of Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany
    • ,
  • N Andratschke

      Affiliations

    • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, Munich, Germany
    • ,
  • C Peschel

      Affiliations

    • Department of Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany
    • ,
  • M Molls

      Affiliations

    • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, Munich, Germany

References 

  1. Tsang RW, Gospodarowicz MK, O’Sullivan B. Staging and management of localized non-Hodgkin’s lymphomas: variations among experts in radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 2002;52:643–651
  2. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma: the international Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–999
  3. Kaminski MS, Coleman N, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann. Int. Med. 1986;104:747–756
  4. Tsang RW, Gospodarowicz MK. Management of localized (stage I and II) clinically aggressive lymphomas. Ann. Hematol. 2001;80(Suppl 3):B66–72
  5. Van der Maazen RW, Noordijk EM, Thomas J, Raemaekers JM, Meerwaldt JH. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin’s lymphoma. Radiother. Oncol. 1998;49:1–7
  6. Zinzani PL, Stefoni V, Tani M, et al.  MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin’s lymphoma patients: 14-year update results. Leuk. Lymphoma. 2001;42:989–995
  7. Miller TP, Dahlberg S, Cassady JR, et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 1998;339:21–26
  8. Glick JH, Kim KJ, Earle J, et al.  An ECOG randomised phase III trial of CHOP versus CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin’s lymphoma (Abstract). Proc. Am. Soc. Clin. Oncol. 1995;14:391
  9. Aviles A, Delgado S, Ruiz H, De la Torre A, Guzman R, Talavera A. Treatment of non-Hodgkin’s lymphoma of Waldeyer’s ring: Radiotherapy versus chemotherapy versus combined therapy. Eur. J. Cancer, Oral Oncol. B. 1996;32:19–23
  10. Oguchi M, Ikeda H, Isobe K, et al.  Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin’s lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:161–168
  11. Shenkier TN, Voss N, Fairey R, et al.  Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol. 2002;20:197–204
  12. Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van’t Veer MB. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin’s lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother. Oncol. 2001;58:252–255
  13. Tondini C, Zanini M, Lombardi F, et al.  Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J. Clin. Oncol. 1993;11:720–725
  14. Miller TP, Leblanc M, Spier C, et al.  CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial (Abstract). Ann. Hematol. 2001;80:B154–155
  15. Fuller LM, Krasin MJ, Velasquez WS, et al.  Significance of tumor size and radiation dose to local control in stage I–III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:3–11
  16. Kamath SS, Marcus RB, Lynch JW, Price Mendenhall N. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 1999;44:563–568
  17. Wilder RG, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, et al. Dose–response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001;49:17–22
  18. Wilder RB, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, et al. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer. 2002;94:601–605
  19. Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, et al. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:743–749
  20. Fisher RI. Current therapeutic paradigm for the treatment of non-Hodgkin’s lymphoma. Semin. Oncol. 2000;27(Suppl 12):2–8
  21. Velasquez W, Fuller LM, Oh KK, et al.  Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas. Cancer. 1984;53:1478–1483
  22. Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz MJ. Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 1994;30:799–803
  23. Schlernbach PJ, Wilder RB, Tucker SL, et al.  Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III–IV, intermediate grade and large-cell immunoblastic lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:1107–1110
  24. Shipp MA, Klatt MM, Yeap B, et al.  Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J. Clin. Oncol. 1989;7:613–618
  25. Coiffier B. Treatment of aggressive non-Hodgkin’s lymphoma. Semin. Oncol. 1999;26:12–20
  26. Ferreri AJ, Dell’Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III–IV diffuse large B-cell lymphomas. Oncology. 2000;58:219–226
  27. Rube C, Nguyen TP, Kloss M, Loeffler M, Trumper L, Pfreundschuh M. Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann. Hematol. 2001;80(Suppl 3):B84–85
  28. Krieger G, Kreysing E, Kneba M. Long-term results with MACOP-B and radiation therapy for aggressive lymphomas (German). Onkologie. 2001;24(Suppl 1):49–58
  29. Bartlett NL, Kwak LW, Horning SJ. MACOP-B±radiation therapy for diffuse large cell lymphoma. Cancer. 1993;71:4034–4042
  30. Schmits R, Glass B, Trumper L, Pfreundschuh M. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL. Ann. Hematol. 2001;80(Suppl 3):B77–83
  31. Ulusakarya A, Lumbroso J, Casiraghi O, et al.  Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin’s lymphoma. Leuk. Lymphoma. 1999;35:579–586
  32. Zinzani PL, Martelli M, Magagnoli M, et al.  Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by scan in 50 patients. Blood. 1999;94:3289–3293
  33. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma—comparison with CT. Leuk. Lymphoma. 2000;39:543–553
  34. Harris N, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  35. Harris N, Jaffe ES, Diebold J, et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999;17:3835–3849

PII: S0305-7372(02)00094-4

doi: 10.1016/S0305-7372(02)00094-4

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 11-19 , February 2003

Article Tools